Aikaterini Ntoskou Messini
Research Subjects
Research Interests
Aikaterini Ntoskou Messini has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Lambros Messinis
Laboratory of Neuropsychology and Behavioral Neuroscience, School of Psychology, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece
2 shared publications - Antonios Mougias
Alzheimer Center of the Greek Psychogeriatric Association “Nestor”, 11144 Athens, Greece
1 shared publication - Christos Bakirtzis
Second Department of Neurology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
1 shared publication - Grigorios Nasios
Department of Speech and Language Therapy, University of Ioannina, 45500 Ioannina, Greece
1 shared publication - Maria Skokou
Laboratory of Neuropsychology and Behavioral Neurosciences, Department of Psychology, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece
1 shared publication - Nikolaos Grigoriadis
Multiple Sclerosis Center, 2nd Department of Neurology, Aristotle University of Thessaloniki, Greece
1 shared publication
Latest Publications
- Open Access
- 21 October 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (10) , 1130
Cognitive Remediation as a Tool for Enhancing Treatment Dimensions of Schizophrenic Symptomatology: A Systematic Review of Randomized Controlled Trials
Background/Objectives: Despite efforts, schizophrenia remains a difficult disease to treat for cognitive, positive, negative, and mood symptoms. In the present review, we explore existing data on the ameliorating effects of neurocognitive rehabilitation and the diverse symptomatology of the disorder. Methods: This systematic review has been registered with PROSPERO (registration number: CRD 420251154674). Following PRISMA guidelines, we conducted a search in PubMed, Scopus, and Science Direct database from inception to 14 July 2025. The methodological quality assessment was made by applying the Joanna Briggs Institute (JBI) critical appraisal tool for systematic reviews. Results: Of the 1001 records screened for eligibility, thirty-five studies were identified for data extraction and synthesis. Of these, seven had a low risk of bias, and seven had a high bias risk. The effects of cognitive remediation on the symptoms of schizophrenia were varied. There are consistently positive effects on negative symptoms, but the findings are mixed regarding other domains of symptomatology. The therapeutic effect on positive psychotic symptoms correlated with the severity of symptoms at baseline. Efficacy for mood and anxiety symptoms is controversial, with a comparable number of studies yielding contradicting results. Conclusions: Cognitive remediation has been shown to represent a significant therapeutic tool for schizophrenia symptoms. The method‘s efficacy seems well-established for negative symptoms, whereas the effects on positive psychotic, mood, and anxiety symptoms, although promising, are currently mixed. More high-quality research targeting patient populations where the symptoms studied are more prominent is needed to clarify the effectiveness of the intervention for distinct dimensions of schizophrenic symptomatology.
- 21 October 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (10) , 1130
Open AccessCognitive Remediation as a Tool for Enhancing Treatment Dimensions of Schizophrenic Symptomatology: A Systematic Review of Randomized Controlled Trials
Background/Objectives: Despite efforts, schizophrenia remains a difficult disease to treat for cognitive, positive, negative, and mood symptoms. In the present review, we explore existing data on the ameliorating effects of neurocognitive rehabilitation and the diverse symptomatology of the disorder. Methods: This systematic review has been registered with PROSPERO (registration number: CRD 420251154674). Following PRISMA guidelines, we conducted a search in PubMed, Scopus, and Science Direct database from inception to 14 July 2025. The methodological quality assessment was made by applying the Joanna Briggs Institute (JBI) critical appraisal tool for systematic reviews. Results: Of the 1001 records screened for eligibility, thirty-five studies were identified for data extraction and synthesis. Of these, seven had a low risk of bias, and seven had a high bias risk. The effects of cognitive remediation on the symptoms of schizophrenia were varied. There are consistently positive effects on negative symptoms, but the findings are mixed regarding other domains of symptomatology. The therapeutic effect on positive psychotic symptoms correlated with the severity of symptoms at baseline. Efficacy for mood and anxiety symptoms is controversial, with a comparable number of studies yielding contradicting results. Conclusions: Cognitive remediation has been shown to represent a significant therapeutic tool for schizophrenia symptoms. The method‘s efficacy seems well-established for negative symptoms, whereas the effects on positive psychotic, mood, and anxiety symptoms, although promising, are currently mixed. More high-quality research targeting patient populations where the symptoms studied are more prominent is needed to clarify the effectiveness of the intervention for distinct dimensions of schizophrenic symptomatology.
- Open Access
- 13 May 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (5) , 906
Comparison of the Greek Version of the Quick Mild Cognitive Impairment Screen and Montreal Cognitive Assessment in Older Adults
Objective: Cognitive screening instruments (CSIs) are essential for everyday practice. The Quick Mild Cognitive Impairment (Qmci) screen, a short instrument designed to identify mild cognitive impairment, was recently translated into Greek (Qmci-Gr). The present study compared its diagnostic value against the Montreal Cognitive Assessment (MoCA) screen and examined its optimal cutoffs. Method: We recruited consecutive patients aged ≥55 years that presented with cognitive complaints from two outpatient clinics in Greece. The Qmci-Gr and MoCA were completed by all patients. Furthermore, they were assessed independently with a comprehensive flexible neuropsychological battery to establish a diagnostic classification. Results: In the current study, we assessed a total of 145 patients, with a median age of 70 years; 44 were classified as having Subjective Memory Complaints (SMC) but normal cognition, 32 with MCI and 69 with dementia. The Qmci-Gr had a higher accuracy compared to the MoCA in discriminating MCI from dementia, area under the curve (AUC) of 0.81 versus 0.75, respectively; however, this finding was marginally significant (p = 0.08). Its accuracy was marginally higher for distinguishing SMC from dementia, AUC of 0.94 versus 0.89 (p = 0.03). However, Qmci-Gr presented a lower accuracy than MoCa in differentiating SMC from MCI, AUC of 0.76 versus 0.94 (p = 0.006). Conclusions: The Qmci-Gr has comparable diagnostic accuracy to the MoCA regarding MCI and dementia groups. Further research, with larger and more diverse samples, may be necessary to ensure generalizability.
- 13 May 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (5) , 906
Open AccessComparison of the Greek Version of the Quick Mild Cognitive Impairment Screen and Montreal Cognitive Assessment in Older Adults
Objective: Cognitive screening instruments (CSIs) are essential for everyday practice. The Quick Mild Cognitive Impairment (Qmci) screen, a short instrument designed to identify mild cognitive impairment, was recently translated into Greek (Qmci-Gr). The present study compared its diagnostic value against the Montreal Cognitive Assessment (MoCA) screen and examined its optimal cutoffs. Method: We recruited consecutive patients aged ≥55 years that presented with cognitive complaints from two outpatient clinics in Greece. The Qmci-Gr and MoCA were completed by all patients. Furthermore, they were assessed independently with a comprehensive flexible neuropsychological battery to establish a diagnostic classification. Results: In the current study, we assessed a total of 145 patients, with a median age of 70 years; 44 were classified as having Subjective Memory Complaints (SMC) but normal cognition, 32 with MCI and 69 with dementia. The Qmci-Gr had a higher accuracy compared to the MoCA in discriminating MCI from dementia, area under the curve (AUC) of 0.81 versus 0.75, respectively; however, this finding was marginally significant (p = 0.08). Its accuracy was marginally higher for distinguishing SMC from dementia, AUC of 0.94 versus 0.89 (p = 0.03). However, Qmci-Gr presented a lower accuracy than MoCa in differentiating SMC from MCI, AUC of 0.76 versus 0.94 (p = 0.006). Conclusions: The Qmci-Gr has comparable diagnostic accuracy to the MoCA regarding MCI and dementia groups. Further research, with larger and more diverse samples, may be necessary to ensure generalizability.